| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Neuroscience (V.P., A.L., S.R.O.), Oregon National Primate Research Center/Oregon Health & Sciences University, Beaverton, Oregon 97006; and Division of Neuroscience (G.C.), Childrens Hospital, Harvard Medical School, Boston, Massachusetts 02115
Address all correspondence and requests for reprints to: Sergio R. Ojeda, Division of Neuroscience, Oregon National Primate Research Center, 505 Northwest 185th Avenue, Beaverton, Oregon 97006. E-mail: ojedas{at}ohsu.edu.
| Abstract |
|---|
|
|
|---|
with production of prostaglandin E2, one of the factors mediating the stimulatory effect of astroglial erbB receptor activation on LHRH release. Medium conditioned by Wa-2+/+ or double-mutant astrocytes treated with TGF
failed to stimulate LHRH release from GT17 cells. The LH response to ovariectomy was significantly attenuated in mutant mice in comparison with wild-type controls. Although the Wa-2 mutation affects all cells bearing erbB-1 receptors, these results suggest that a major defect underlying the reproductive defects of animals with impaired erbB signaling is a decreased ability of glial cells to stimulate LHRH release. Thus, a coordinated involvement of erbB-1 and erbB-4 signaling systems is required for the normalcy of sexual development and the maintenance of mature female reproductive function. | Introduction |
|---|
|
|
|---|
Activation of LHRH neurons is thought to occur both in response to changing inputs from synaptically connected neuronal networks and via the activation of growth factor-dependent glia-to-neuron signaling pathways (for review see Ref.1). One of these pathways uses the epidermal growth factor (EGF)-related peptides, TGF
and neuregulins (NRGs), and their cognate receptors, erbB-1 and erbB-4, to set in motion astroglial-LHRH neuron communication (reviewed in Ref.2). In vitro studies showed that TGF
and NRGs produced by glial cells do not stimulate LHRH secretion directly; instead, they do so by acting in an autocrine and/or paracrine fashion on astrocytes themselves where activation of erbB signaling results in prostaglandin E2 (PGE2) release. Upon release from astrocytes, PGE2 acts on LHRH neurons to elicit LHRH secretion (3, 4, 5). In line with these studies, pharmacological blockade of erbB-1 receptor at the median eminence (6) or antisense oligonucleotide-mediated inhibition of erbB-2 receptor synthesis (5) delayed the onset of female puberty in rats. Although erbB-2 receptors do not bind any known member of the EGF family of ligands, they are recruited by activated erbB-1 or erbB-4 receptors to form heterodimeric complexes that enhance downstream signaling (7). To assess the role of glial erbB-3, erbB-4 and erbB-2 receptors in female sexual development, we engineered transgenic mice in which the function of these receptors is disrupted specifically in astroglial cells by the targeted expression of a dominant-negative (DN) truncated form of the receptor (DNerbB-4) (8). Because hypothalamic astrocytes do not express erbB-3 receptors (5), the mutant erbB-4 protein is expected to only affect astroglial erbB-4/erbB-2 signaling. Expression of this truncated form in astrocytes reduces the ability of these cells to respond to NRG stimulation with production of PGE2 and also impairs NRG-induced LHRH release from neuroendocrine terminals of the median eminence, without affecting the ability of these nerve endings to respond to PGE2 with LHRH release (8). In accordance with this deficit in LHRH secretion, female mice carrying the DNerbB-4 transgene exhibited delayed sexual maturation and a diminished reproductive capacity in early adulthood (8).
Despite the unavailability of an animal model in which the function of erbB-1 signaling is compromised in a cell-specific manner, alternative genetic approaches have been used to gain insights into the involvement of TGF
/erbB-1 signaling in the control of female sexual maturation. Thus, the transgenic overexpression of TGF
, and the intrahypothalamic grafting of cells engineered to produce TGF
have been shown to advance female puberty in rats (9, 10). In keeping with these observations, mice harboring the naturally occurring recessive Wa-2 point mutation in the tyrosine kinase domain of the erbB-1 receptor (11, 12) have also been shown to have delayed puberty (13).
Here we report that mice carrying both the Wa-2 mutation and a DNerbB-4 mutant receptor selectively expressed in astrocytes exhibit a more pronounced delay in the onset of puberty and a dramatically impaired adult reproductive function in comparison to single-mutant mice and wild-type animals. These defects appear to be caused, to a significant extent, by loss of erbB receptor-mediated astrocyte-to-neuron communication. These results indicate that the glial erbB-1/erbB-2 and erbB-4/erbB-2 receptor systems act coordinately in the hypothalamic control of reproductive function.
| Materials and Methods |
|---|
|
|
|---|
To generate double mutant mice, homozygous Wa-2 male mice were crossed to homozygotes DNerbB-4 to obtain double heterozygous mice. DNerbB-4 homozygous mice were identified by crossing DNerbB-4-positive animals with wild-type mice. After genotyping the resulting progenies, those parents that produced three consecutive litters in which all pups were positive for the transgene were considered to be homozygous. The double heterozygous DNerbB-4+/Wa-2+/ animals were bred among themselves to obtain the four desired genotypes: wild-type, DNerbB-4+/Wa-2/, DNerbB-4//Wa-2+/+, and DNerbB-4+/Wa-2+/+ (double mutant). Although animals carrying the DNerbB-4 transgene driven by the GFAP promoter were identified by genotyping (8), Wa-2+/+ mice were identified by their curly whiskers, vibrissae, and guard hairs, a pleiotropic recessive effect of the erbB-1 receptor point mutation (http://jaxmice.jax.org/library/notes/index.html) (11).
Evaluation of sexual maturation and adult reproductive function
To determine whether the astrocytic blockade of erbB4 signaling combined with a defective erbB-1 receptor have a cumulative effect on female sexual maturation, wild-type, single mutant and double mutant littermates were inspected daily for imperforation of the vaginal membrane (vaginal opening), starting on postnatal d 26. Thereafter, vaginal lavages were performed daily to identify the occurrence of the first estrus, which in rodents is manifested by a predominance of cornified cells (14). Although ovulation normally occurs on the day of estrous (14), detection of cornified cells in mice cannot be assumed to indicate that ovulation has occurred, unless vaginal cornification is followed by the appearance of a predominance of leukocytes (15). This feature defines the diestrous phase of the estrous cycle, and indicates that a functional corpus luteum was formed after ovulation. Therefore, a true first estrus (and thus the age at first ovulation) was considered to have occurred only when the cornified cells were replaced by at least 2 d of lavages containing mostly leukocytes (8).
To examine the effect of defective erbB-4 and erbB-1 signaling on adult reproductive capacity, young adult (50 d old) female mice of each of the four aforementioned genotypes were exposed to a fertile male of identical genotype (one male per female). Thereafter, litter birth and size were recorded for at least 6 consecutive months for each breeding pair. The fertility index was calculated by dividing the number of litters recorded by the number of months during which each dam was monitored. The mean number of pups per litter was also calculated for each dam. The figures obtained from each independent breeding pair of each genotype were then collapsed into single means, which were used as independent observations to generate the overall mean for each group. The breeding capacities of single and double mutant male mice were assessed by the ability of these animals to produce two litters of normal size within 50 d of exposure to a wild-type female.
Antibodies, growth factors, and prostaglandins
Human recombinant TGF
was supplied by Upstate (Lake Placid, NY), NRGß1 was purchased from Neomarkers (Union City, CA), ß-cellulin from R&D Systems (Minneapolis, MN), and PGE2 was obtained from Sigma (St. Louis, MO). erbB-1 receptors were immunoprecipitated using sheep polyclonal antibodies (Fitzgerald Industries, Concord, MA) and were detected in Western blots with goat polyclonal antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), as described (8). erbB-2 receptors were both immunoprecipitated and detected in immunoblots with rabbit polyclonal antibodies (SC-284, Santa Cruz). Phosphorylated erbB-1 and erbB-2 were detected with an antiphosphotyrosine monoclonal antibody (4G10) generously provided by Dr. Brian Drucker (Oregon Health & Sciences University, Portland, OR). The antibodies used to detect ERK1/2 (p44/p42 MAPK), and phospho-ERK1/2 were obtained from Cell Signaling Technology, Inc. (Beverly, MA). The secondary antibody, antimouse IgG peroxidase [horseradish peroxidase (HRP)], and the antirabbit IgG peroxidase (HRP) used in Western blots were from Pierce (Rockford, IL) and from Zymed Laboratories (South San Francisco, CA), respectively. The Anti-Goat/Sheep peroxidase (HRP) (Clone GT-34) was from Accurate Chemicals & Scientific Co. (Westbury, NY).
Cell culture
Astrocytes were isolated from the whole brain of 1- to 2-d-old wild-type and mutant mice and cultured as previously described (5, 8). Initially, each culture derived from a single brain. Once the genotype of the donor animal was established, the cultures to be employed for Western blots (see Immunoprecipitation and Western blots) were kept as individual cultures until conducting the experiment proper. The cultures to be used for PGE2 and astrocyte-conditioned medium (ACM)-evoked LHRH release were pooled (two to three brains from the same genotype) before replating the astrocytes before the experiment (see below). In all cases, the cells were dispersed upon brain collection, and were first grown for 810 d in 75-cm culture flasks containing DMEM-F12 medium supplemented with 10% donor calf serum (Hyclone, Logan, UT). At this time, the astrocytes were isolated from other cell types by overnight shaking at 250 rpm and replated in either 15-cm dishes for immunoblots or 12-well plates for prostaglandin release experiments. After reaching 8090% confluence, the medium was replaced with a serum-free, astrocyte-defined medium (DMEM supplemented with putrescine-100 µM and insulin (5 µg/ml) (5), and the cultures were used 4 d later for the experiments. To examine the effect of TGF
on PGE2 release, the cells were incubated with the growth factor (at 100 ng/ml) for 16 h at 37 C. For erbB1/erbB2 and ERK 1/2 phosphorylation studies, TGF
, NRGß1, and ß-cellulin were added to the cultures for 5 min, and the cells were snap-frozen for subsequent protein extraction and SDS-PAGE analysis.
To assess the effect of astrocyte-derived substances on LHRH release, the GT17 immortalized LHRH-secreting cell line was used. The cells were plated (100,000 cells per well) in a 24-well plate and cultured with DMEM containing 10% fetal calf serum, penicillin (100 U/ml), and streptomycin (100 µg/ml) for 24 h. Thereafter, the medium was replaced with serum-free neuronal defining medium for 24 h. Neuronal defined medium consisted of glutamate-free DMEM with transferring (100 µg/ml), putrescine (100 µM), L-glutamine (2 mM), sodium selenite (30 nM), and insulin (5 µg/ml). The cells were exposed to 0.5 ml of culture medium conditioned by brain astrocytes treated for 16 h with or without TGF
ACM. After a 30-min exposure to ACM, the medium was collected, boiled, and stored at 20 C until LHRH measurement.
Immunoprecipitation and Western blots
Cell cultures were lysed in immunoprecipitation assay buffer, and the extracted proteins were size-fractionated and transferred to polyvinylidene difluoride (Millipore, Billerica, MA) membranes, as described (5, 16). To identify phosphorylated erbB-1 and erbB-2 receptors, the receptors were immunoprecipitated using the polyclonal antibodies sc-03-G and sc-284 (Santa Cruz), respectively, electrophoresed, and immunoblotted with phosphotyrosine antibody 4G10, exactly as reported (8). To develop the immunoreaction, the blots were incubated with horseradish peroxidase-conjugated secondary antibodies (Zymed, San Francisco, CA), developed using enhanced chemiluminescence (PerkinElmer, Boston, MA), and exposed to film. After stripping (8), the membranes were reprobed with the same erbB-1 or erbB-2 antibodies used for immunoprecipitation to control for procedural variability.
To detect ERK1/2 phosphorylation, protein extracts (20 µg protein per well) were loaded into an SDS-PAGE 420% polyacrylamide gel (Invitrogen Life Technologies, Carlsbad, CA), electrotransferred to a polyvinylidene difluoride membrane, blocked with 2.5% gelatin, and blotted with phospho ERK1/2 antibodies (Cell Signaling) diluted 1:1000. After incubation with horseradish peroxidase-conjugated secondary antibodies (Zymed, 1:5000), the membranes were treated with enhanced chemiluminescence reagents (PerkinElmer) and exposed to film. Thereafter, the membranes were reprobed with antibodies against nonphosphorylated ERK1/2 (Cell Signaling).
Ovariectomy
Ovariectomy was performed on postnatal d 24. The ovaries were aseptically removed from animals anesthetized with isoflurane, via a single dorsal skin incision followed by blunt separation of the underlying muscle-aponeurosis interface. Different groups of mice were killed 24 and 96 h later.
Measurements of LHRH, PGE2, and serum LH
PGE2 released from astrocytes in response to TGF
, and LHRH released from GT17 cells in response to ACM, were detected by RIA, as described previously (8, 17). Serum levels of LH were measured by RIA as reported (8).
Statistics
The differences between several groups were analyzed by ANOVA followed by the Student-Newman-Keuls multiple comparison test for unequal replications. The Students t test was used to compare two groups. When comparing percentages, groups were subjected to arc-sine transformation before statistical analysis to convert them from a binomial to a normal distribution (18).
| Results |
|---|
|
|
|---|
|
|
|
-dependent erbB-1/erbB-2signaling in astrocytes
to signal via erbB-1 receptors in astrocytes is also affected. To address this issue, we used primary cultures of brain astrocytes. Immunoprecipitation combined with Western blot analysis showed that TGF
-induced phosphorylation of astrocytic erbB-1 receptor was diminished by 50% in astrocytes from Wa-2+/+ mice in comparison to wild-type astrocytes (Fig. 4A
|
, NRGß1, or ß-cellulin (at 50 ng/ml each) to differentially activate erbB-1, erbB-4, or both signaling pathways, respectively. Treatment of wild-type astrocytes with each of these ligands resulted in the expected increase in ERK1/2 phosphorylation (Fig. 5A
and ß-cellulin, but not to NRGß1 (Fig. 5B
but responded well to both NRGß1 and ß-cellulin (Fig. 5C
|
-induced release of PGE2 from astrocytes and ACM-induced LHRH release from GT17 cells
stimulates LHRH release via a glial intermediacy that involves activation of astrocytic erbB-1 receptors and the subsequent release of PGE2 (3), which then binds to specific receptors on LHRH neurons (4) to elicit LHRH release. To determine whether this pathway was affected in astrocytes from Wa2+/+ mice, we assessed the PGE2 response of these cells to TGF
, and the LHRH response of GT17 cells to the culture medium of astrocytes treated with TGF
. Although, as shown previously (8), both wild-type and DNerbB-4 astrocytes responded to TGF
(100 ng/ml, 16 h exposure) with a significant increase in PGE2 release, Wa2+/+ astrocytes failed to do so (Fig. 6A
released LHRH in response to the ACM derived from wild-type and DNerbB-4 astrocytes treated with TGF
but failed to release the decapeptide when exposed to ACM derived from TGF
-treated Wa-2+/+ or double mutant astrocytes (Fig. 6B
to activate the PGE2-dependent glia-to neuron communication required for glial control of LHRH secretion.
|
|
| Discussion |
|---|
|
|
|---|
The complementary involvement of glial erbB-1 and erbB-4 signaling pathways in the paracrine control of LHRH release was first suggested by in vitro experiments demonstrating that cotreatment of hypothalamic astrocytes with low doses of NRG and TGF
, that by themselves were ineffective, resulted in PGE2 production (5). Additional evidence suggesting that coregulation of glial erbB-1 and erbB-4 signaling system by physiological stimuli is an important component of neuroendocrine neuron-glia communication was provided by the demonstration that concomitant activation of metabotropic and amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptors promotes ligand-dependent activation of both erbB1 and erbB-4 receptors in hypothalamic astrocytes (20). Because an increase in glutamatergic neurotransmission appears to be one of the primary events underlying the advent of puberty (1), these findings suggested that the facilitatory control exerted by glutamatergic neurons on LHRH release also involves the coordinated activation of a dual, erbB-1/erbB-4-dependent glia-to-neuron communication pathway.
The close coordination of ligand-induced erbB signaling in astrocytes may be directly linked to the ability that erbB-1 shares with erbB-4 to induce phosphorylation of erbB-2 coreceptors. Ligand-promoted phosphorylation of erbB-2 via the formation of erbB-4/erbB-2 heterodimers is abrogated in DNerbB-4 astrocytes (8). Here we show that the ability of erbB-1 receptors to transphosphorylate erbB-2 coreceptors is also impaired in Wa-2+/+ astrocytes. The physiological importance of these effects is demonstrated by the delay sexual maturation observed in rats in which erbB-2 synthesis was selectively inhibited using antisense oligodeoxynucleotides (5). Interestingly, and as shown for other glial cell types (21, 22), a certain degree of erbB-2 heterodimerization with erbB-1 (this study) and erbB-4 receptors (5) occurs in astrocytes in the absence of exogenous ligand stimulation. This physical association might be driven by endogenous erbB ligands produced by astrocytes themselves (5, 23). Such an interaction might enable hypothalamic astrocytes to sense microchanges in their extracellular environment like the processing of erbB ligand precursors by matrix metalloproteinases (24, 25). An increase in metalloproteinase activity has been shown to be required for glutamate receptors to transactivate both erbB-1 and erbB-4 receptors in hypothalamic astrocytes (20).
Because the Wa-2 mutation affects all cells containing erbB-1 receptors, it is unlikely that the defects in reproductive function detected in these and double-mutant mice are only the consequence of a central defect. However, the alterations in glial erbB-1 signaling, astrocytic PGE2 release, neuronal LHRH release in response to ACM, and LH response to ovariectomy clearly demonstrate the existence of a central defect. A previous study arrived to a similar conclusion by demonstrating that the Wa-2 mutation disrupts the synchrony that exists between behavioral estrus and ovulation, and by showing that central, pharmacological blockade of erbB-1 receptors resulted in similar abnormalities (13). Again, it is possible that the diminished fertility observed in Wa-2+/+ and double-mutant mice are secondary to defects in sexual behavior. Without denying the potential contribution of such defects, the clear-cut deficiency in astrocyte-induced LHRH release associated with the Wa-2+/+ phenotype argues strongly for the existence of a central, neuroendocrine defect contributing to the delay in puberty and the diminished fertility observed in these mutant mice. This conclusion is further supported by the impaired ability of Wa-2+/+, DNerbB-4+ and double-mutant juvenile mice to respond with LH release to removal of the ovaries. The lack of alterations in body weight in double-mutant mice reinforces this view. Because this is the group exhibiting the most pronounced alterations in reproductive function, and yet it grows normally, it would not appear that alterations in the output of pituitary hormones either controlling or influencing growth are responsible for the reproductive defects observed. A very interesting aspect of the present study is the finding that male reproductive function was not affected by the disruption of erbB-1/erbB-4 receptors. A strong precedent for this notable sex difference does indeed exist because several null mutations that cause female infertility have no effect on male reproductive capacity. Prominent examples can be found in the targeted disruption of the cyclooxygenase (26), progesterone receptor (27), and FSH (28) genes.
In summary, the present results demonstrate that the functional integrity of both erbB-1 and erbB-4 signaling system in hypothalamic astrocytes is critical for glial cells to engage in neuron-glia interactions able to facilitate LHRH secretion at the time of puberty. This functional integrity also appears to be an important component of the central mechanism controlling female reproductive function in adulthood.
| Footnotes |
|---|
Present address for V.P.: Institut National de la Santé et de la Recherche Médicale Unité 422, Place de Verdum, 59045 Lille Cedex, France.
First Published Online December 9, 2004
Abbreviations: ACM, Astrocyte-conditioned medium; DM, dominant-negative; EGF, epidermal growth factor; HRP, horseradish peroxidase; NRG, neuregulin; PGE2, prostaglandin E2.
Received August 30, 2004.
Accepted for publication November 29, 2004.
| References |
|---|
|
|
|---|
(TGF
) gene expression in the hypothalamus is developmentally regulated and linked to sexual maturation. Neuron 9:657670[CrossRef][Medline]
) transgene reveals a dual antagonistic role of TGF
in female sexual development. Endocrinology 135:13921400[Abstract]
expression to discrete loci of the neuroendocrine brain induces female sexual precocity. Proc Natl Acad Sci USA 94:27352740
(TGF
) gene expression in astrocytes of the neuroendocrine brain. J Neurosci 14:56445651[Abstract]
(proTGF-
). Biochemistry 42:21272136[CrossRef][Medline]
-converting enzyme. Mol Cell Neurosci 16:631648[CrossRef][Medline]
This article has been cited by other articles:
![]() |
A. A Gratao, M. Dahlhoff, F. Sinowatz, E. Wolf, and M. R Schneider Betacellulin Overexpression in the Mouse Ovary Leads to MAPK3/MAPK1 Hyperactivation and Reduces Litter Size by Impairing Fertilization Biol Reprod, January 1, 2008; 78(1): 43 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takagi, T. Yamamura, T. Anraku, S. Yasuo, N. Nakao, M. Watanabe, M. Iigo, S. Ebihara, and T. Yoshimura Involvement of Transforming Growth Factor {alpha} in the Photoperiodic Regulation of Reproduction in Birds Endocrinology, June 1, 2007; 148(6): 2788 - 2792. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hsieh, D. Lee, S. Panigone, K. Horner, R. Chen, A. Theologis, D. C. Lee, D. W. Threadgill, and M. Conti Luteinizing Hormone-Dependent Activation of the Epidermal Growth Factor Network Is Essential for Ovulation Mol. Cell. Biol., March 1, 2007; 27(5): 1914 - 1924. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Conti, M. Hsieh, J.-Y. Park, and Y.-Q. Su Role of the Epidermal Growth Factor Network in Ovarian Follicles Mol. Endocrinol., April 1, 2006; 20(4): 715 - 723. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Ojeda, A. Lomniczi, C. Mastronardi, S. Heger, C. Roth, A.-S. Parent, V. Matagne, and A. E. Mungenast Minireview: The Neuroendocrine Regulation of Puberty: Is the Time Ripe for a Systems Biology Approach? Endocrinology, March 1, 2006; 147(3): 1166 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lomniczi, A. Cornea, M. E. Costa, and S. R. Ojeda Hypothalamic Tumor Necrosis Factor-{alpha} Converting Enzyme Mediates Excitatory Amino Acid-Dependent Neuron-to-Glia Signaling in the Neuroendocrine Brain J. Neurosci., January 4, 2006; 26(1): 51 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-K. Han, M. L. Gottsch, K. J. Lee, S. M. Popa, J. T. Smith, S. K. Jakawich, D. K. Clifton, R. A. Steiner, and A. E. Herbison Activation of Gonadotropin-Releasing Hormone Neurons by Kisspeptin as a Neuroendocrine Switch for the Onset of Puberty J. Neurosci., December 7, 2005; 25(49): 11349 - 11356. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |